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ABSTRACT The basal forebrain cortical cholinergic system (BFCS) is critical for
the regulation of attentional information processing. BFCS activity is regulated by
several cortical and subcortical structures, including the nucleus accumbens (NAC)
and prefrontal cortex (PFC). GABAergic projection neurons from NAC to basal fore-
brain are modulated by Glu receptors within NAC. We previously reported that intra-
NAC perfusions of NMDA or its antagonist CPP stimulate ACh release in PFC. In
this experiment we determined whether this trans-synaptic modulation of cortical
ACh release is evident in multi-sensory associational areas like the posterior parietal
cortex (PPC). Artificial cerebrospinal fluid (aCSF, control), NMDA (250 or 400 mM), or
CPP (200 or 400 mM) were perfused into the NAC shell and ACh was measured in the
ipsilateral PPC. Amphetamine (2.0 mg/kg, i.p), was systemically administered as a
positive control in a fourth session, since it also stimulates cortical ACh release but
via mechanisms known to not necessitate transmission within the NAC. Neither
NMDA nor CPP increased ACh efflux in the PPC, yet both drugs increased ACh
release in PFC, suggesting that NMDA receptor modulation in the NAC increases
ACh in the cortex in a regionally-specific manner. Systemic amphetamine administra-
tion significantly increased (100–200%) ACh in the PPC, suggesting that levels of ACh
in the PPC can be increased following certain pharmacological manipulations. The
cortical region-specific modulation of ACh by NAC may underlie the linkage of motiva-
tional information with top-down controls of attention as well as guide appropriate
motor output following exposure to salient and behaviorally relevant stimuli. Synapse
61:115–123, 2007. VC 2006 Wiley-Liss, Inc.
INTRODUCTION
The cholinergic projections from the basal forebrain
project to all areas and layers of the neocortex
(Mechawar et al., 2000). This basal forebrain cortical
cholinergic system (BFCS) has been demonstrated to
be critical for normal attentional processing (Dalley
et al., 2004; Mizra and Stolerman, 1998; Muir et al.,
1995; Sarter et al., 2005a). Furthermore, dysregula-
tions in the functioning of this system have been
postulated to contribute to the cognitive deficits
accompanying several neuropsychiatric disorders
(Isacson et al., 2002; Sarter and Bruno, 1997; Sarter
et al., 2005b; Tandon et al., 1991). A two-tiered model
has been proposed, suggesting that attentional pro-
cessing during sensory orienting is achieved by two
separate but interacting circuits: a dorsal and a
ventral attention system. The ventral system medi-
ates signal-based or stimulus-driven aspects of atten-
tion and its operations are referred to as bottom-up
processing. The dorsal system involves modulation of
attentional function through knowledge-based or exe-
cutive control and its operations are referred to as
top-down processing (Corbetta and Shulman, 2002;
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Fox et al., 2006; Posner and Petersen, 1990; Sarter
et al., 2001, 2005a).
The prefrontal cortex (PFC) is a central component
of the dorsal attentional system, participating in the
regulation of attentional processes particularly under
conditions when the salience of the signal is low, irrele-
vant information must be filtered, or biases of stimu-
lus selection are warranted (Posner and Petersen,
1990; Sarter et al., 2001). The PFC contributes top-
down control over attentional processing through
multi-synaptic projections to other cortical regions
(such as posterior parietal cortex, PPC) or corticofugal
projections to basal forebrain (Nelson et al., 2005;
Zaborszky and Duque, 2000). An additional circuit
contributing to the linking of motivational states and
attentional priorities is the link between PFC and the
nucleus accumbens (NAC; Pinto and Sesack, 2000;
Reynolds and Zahm, 2005). Projections from the shell
region of the NAC to cholinergic neurons of the basal
forebrain (Zaborszky and Cullinan, 1992) would then
influence projections of the BFCS (Moore et al., 1999;
Neigh et al., 2004).
We previously reported, using dual probe microdialy-
sis experimental designs, that intra-NAC perfusions of
NMDA receptor agonists and antagonists into the shell
region of the NAC result in increased ACh release in
PFC in awake yet resting rats (Neigh-McCandless
et al., 2002; Zmarowski et al., 2005). We postulated that
changes in NMDA receptor activity in NAC that serve
to modulate cholinergic input to PFC may, in part,
reflect a neuronal circuit that participates in the top-
down controls of attentional processing. As such, we
would expect that these NMDA-receptor-induced
changes in cortical ACh release are restricted to the
prefrontal region and do not, under conditions in which
the animal is at rest, extend to other cortical regions
participating in attentional processing such as the
PPC. In the present experiment, NMDA or the NMDA
antagonist CPP were perfused into the NAC shell and
ACh release was determined in PPC. As a positive con-
trol for the ability to stimulate ACh release in PPC,
animals also received a systemic injection of ampheta-
mine. We have previously shown that amphetamine-
induced ACh release does not involve transmission
within NAC (Arnold et al., 2000).
MATERIALS AND METHODS
Subjects
Male Wistar rats (Charles River Labs, Wilmington,
MA) weighing between 300 and 400 g were utilized
for all studies. Animals were maintained on a 12:12 h
light:dark cycle (lights on: 0600) in a temperature-
and humidity-controlled room. Animals were individ-
ually housed in plastic cages lined with corn cob bed-
ding (Harlan Teklad, Madison, WI) and had access to
food and water ad libitum. All procedures involving
animals were approved by The Ohio State University
Institutional Animal Care and Use Committee in ac-
cordance with the NIH Guide for the Care and Use of
Laboratory Animals.
Three days prior to surgery, animals were accli-
mated to the microdialysis testing environment in
clear plastic bowls (35  38 cm (height  diameter);
CMA, Stockholm, Sweden) lined with corn cob bed-
ding. Animals remained in the bowls for a minimum
of 4 h/day, and returned to their home cages at the
end of each acclimation period.
Surgery
Following 3 days of acclimation, animals were anes-
thetized using isoflurane gas (2%, 0.6 L/min, O2 deliv-
ery) and unilaterally implanted with microdialysis
guide cannuale (0.38 mm o.d.; Sci Pro, Sanborn, NY)
into the nucleus accumbens shell (NAC; in mm from
bregma: AP þ1.3, ML 61.0, DV –5.8), and the ipsilat-
eral posterior parietal cortex (PPC; in mm from
bregma: AP –4.4, ML 61.5, DV –0.5, with the tip of
the guide oriented at 458 laterally). Cannuale were
inserted with dummy stylets to prevent occlusion. All
guide cannulae were fixed using dental cement and
three stainless steel skull screws. The surgical site
was swabbed with a topical antibiotic ointment (lido-
cane, 5%), and animals received a prophylactic dose
of the antibiotic amoxicillin (100 mg/kg) subcutane-
ously. Animals were allowed to recover for 3 days fol-
lowing surgery while being further acclimated daily
to the microdialysis testing environment.
Experimental procedures
Animals (n ¼ 6) were tested four times, with a dif-
ferent pharmacological manipulation (vehicle-aCSF,
250 mM NMDA or 200 mM CPP), administered, in
counterbalanced order, every other day. As a positive
control, last dialysis session consisted of administra-
tion of amphetamine (2.0 mg/kg, i.p.), a manipulation
known to increase cortical ACh via mechanisms that
do not necessitate changes in NAC transmission
(Arnold et al., 2000). Following the 3-h wash-out pe-
riod, four baseline samples were collected; 15 min col-
lection intervals were observed with all time points.
Following the four baseline collections, the syringe
was switched from aCSF to one containing aCSF þ
drug (250 mM NMDA, 200 CPP, or aCSF vehicle). Fol-
lowing a 15-min wash-out, four additional collections
were taken before switching the syringe back to one
containing only aCSF. This perfusion lasted a total of
60 min, including an initial 15-min wash-out period.
Following the last collection, probes were removed
and stylets were reinserted before returning animals
to their home cages. For the last session, dialysis was
conducted as described above through the 3-h wash-
out period and the four baseline collections. After the
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completion of baseline collections, animals received
amphetamine (2.0 mg/kg, i.p.). A total of eight drug
collections (15 min each) were taken immediately fol-
lowing the injection; no 15-min wash-out period was
observed. Following the last collection, probes were
removed and stylets were reinserted as described
above.
The effects of higher concentrations of these drugs
were assessed in a separate group of animals (n ¼ 6),
to test for any concentration-dependent changes in
ACh efflux. Sessions were conducted in the exact
same manner as described above, except the original
concentrations of the NMDA receptor ligands were
replaced with 400 mM NMDA, and 400 mM CPP.
General microdialysis procedures
Microdialysis sessions were conducted using
repeated perfusions, with each animal receiving four
different pharmacological manipulations, one every
other day. This repeated testing paradigm has the
advantage of decreasing variability among treatment
conditions because each subject serves as its own con-
trol. Furthermore, it allows for paradigms such as
dose-response analyses, as well as agonist-antagonist
interactions to be studied in the same animal. The
procedure has been repeatedly validated by demon-
strating that basal cortical ACh efflux does not signif-
icantly change over repeated dialysis sessions, and
that the effects of behavioral, pharmacological, or sen-
sory manipulations on ACh levels do not interact
with dialysis sessions (Bruno et al., 1999; Nelson
et al., 2000).
On the fourth day following surgery, animals were
brought to the testing environment and allowed to ac-
climate for 30 min prior to the insertion of microdialy-
sis probes. Following the 30 min acclimation period,
stylets were removed and probes (Sci Pro, 0.2 mm
o.d., 3.0 mm membrane tip for PPC, 0.2 mm o.d.,
2.0 mm membrane tip for NAC) were inserted into
each guide.
Probes were continuously perfused with artificial
cerebral spinal fluid (aCSF; containing in mM: NaCl
166.5, NaHCO3 27.5, KCL 2.4, CaCl2 1.2, Na2SO4 0.5,
KH2PO4 0.5, glucose 1.0, pH 7.1) at a flow rate of
1.25 ml/min. No acetylcholinesterase inhibitor was uti-
lized in any experiment. A 3-h wash-out period was
observed after probe insertion to allow ACh efflux to
reach a stable baseline that was maximally sensitive
to TTX before beginning collections (Moore et al.,
1992).
HPLC analysis
Dialysis samples were stored at 808C until ana-
lyzed using high performance liquid chromatography
(HPLC) with electrochemical detection. A volume of
15 ml of each sample was injected by autosampler
(ESA, Chelmsford, MA). ACh and choline were sepa-
rated by an UniJet microbore analytical column
(BAS; 1  50 mm2) using a sodium phosphate mobile
phase (35 mM Na2HPO4, 484 mM EDTA, 0.005%
microbicide reagent ProClin, pH ¼ 8.5, flow rate ¼
0.15 ml/min). A precolumn immobilized enzyme reac-
tor (IMER; BAS) was used to hydrolyze choline, and a
postcolumn IMER containing acetylcholinesterase
and choline oxidase was used to break down ACh into
H2O2 (Potter et al., 1983), and quantified using a per-
oxidase-wired ceramic glassy carbon electrode (Model
no. 5041 microdialysis analytical cell, ESA).
Histology
Following the final microdialysis session, animals
were given an overdose of sodium pentobarbital and
transcardially perfused with 0.9% heparinized saline
followed by 10% formalin. Brains were removed and
stored in 10% formalin for at least 24 h, and were
then transferred to a 30% sucrose solution for 3 days.
Brains were sectioned (50 mM) using a cryostat,
mounted on gelatin-coated slides, stained using Cre-
syl Violet, and examined under a light microscope.
Subjects whose probes were located outside any of the
targeted regions were excluded from further analysis.
Data analysis
The effects of individual drug treatments on PPC
release were analyzed using separate ANOVAs. Fur-
thermore, to illustrate the contrast between the pres-
ent results on PPC ACh release and prior evidence on
PFC release, the prior data are reproduced in the fig-
ures. These regional comparisons are justified by the
fact that the studies conducted in the present experi-
ment and our previous reports utilized identical
microdialysis and testing methods.
Changes in basal ACh efflux (fmol/15 ml) across ses-
sions and treatment groups were analyzed using one-
way repeated measures analysis of variance
(ANOVAs). In the absence of any session or group
effects, basal efflux was then defined as the mean of
the four baseline collections, and subsequent data
were expressed as percent change from that mean
baseline. Overall statistical analysis of drug effects
was conducted using a two-way, within-subjects
ANOVA with drug GROUP and TIME as within-sub-
jects measures. In some cases, one-way ANOVAs were
conducted for each drug with TIME as a repeated,
within-subject measure (a ¼ 0.05). The Huynh-Feldt
correctionwas utilized to reduce Type I errors associated
with repeated measures ANOVAs (Vasey and Thayer,
1987). Exact P-values were reported (Greenwald et al.,
1996). All statistical tests were preformed using SPSS
for windows (V14.0, Chicago, IL).




Figure 1 shows representative placements of micro-
dialysis probes in the shell region of the NAC
(Fig. 1A,B) and the ipsilateral PPC (Fig. 1C,D). Ani-
mals whose probe placements fell outside the NAC
shell or PPC were excluded from further analysis.
Basal levels of ACh efflux in PPC
Basal levels of ACh efflux were stable over the four
dialysis SESSIONs (F3, 15 ¼ 2.227, P ¼ 0.127), and
across the four treatment GROUPs (F3, 15 ¼ 1.327,
P ¼ 0.305). Basal levels of ACh (mean 6 SEM, fmol/
15 ml) were 8.1 6 2.5, 9.8 6 1.9, 7.0 6 1.5, and 5.0 6
1.7 for aCSF, 250 mM NMDA, 200 mM CPP, and am-
phetamine sessions, respectively. Given that basal
levels of ACh efflux did not differ over session or
group, all subsequent values were expressed and ana-
lyzed as a percent change from session baseline.
Regional effects of NMDA
Figure 2 illustrates that the effects of NMDA on
ACh efflux differed markedly between PFC and PPC.
Fig. 1. A: depicts a schematic of a NAC placement. Guides were
implanted so that when probes were inserted (2 mm active tip), the
membrane tip was located in the shell region of the NAC. B: is a
photomicrograph of a representative NAC shell placement illus-
trated in Panel A. The area between the arrows represents the
active membrane tip (2.0 mm). C: depicts a schematic representation
of a PPC placement. Guides were implanted so that when probes
were inserted, the membrane tip was located in the PPC with the
tip of the guide oriented at 458 laterally. D: is a photomicrograph
that is representative of the PPC placement illustrated in Panel C.
The area between the arrows represents the active membrane tip
(3.0 mm).
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As reported previously, intra-NAC perfusions of
NMDA (250 mM) stimulated ACh efflux, relative to
the aCSF control session, in PFC (Zmarowski et al.,
2005). In contrast, similar infusions of NMDA did not
stimulate ACh efflux, relative to the aCSF control
session, in PPC (F1, 5 ¼ 3.138, P ¼ 0.137).
Regional effects of CPP
Figure 3 illustrates that the effects of intra-NAC
administration of the NMDA antagonist CPP on ACh
release differed in PFC and PPC. We previously
reported that intra-NAC perfusions of CPP (200 mM)
produced a robust and long-lasting stimulation of
ACh efflux, relative to the aCSF control session, in
PFC (Neigh-McCandless et al., 2002). In contrast,
similar infusions of CPP did not stimulate ACh efflux,
relative to the aCSF control session, in PPC (F1, 5 ¼
3.31, P ¼ 0.128).
Effects of higher concentrations of drugs on
ACh release in PPC
A separate group of animals was tested with a
higher concentration of either NMDA or CPP to
determine if the cortical differences reflected a right-
ward shift in the dose response curve for ACh release
in PPC. Basal levels of efflux were stable over the
four dialysis SESSIONs (F3, 15 ¼ 2.962, P ¼ 0.116) as
revealed by one-way ANOVAs. Basal levels of ACh
(mean 6 SEM, fmol/15 ml) were 6.0 6 1.1, 8.9 6 2.6,
8.1 6 1.6, and 2.7 6 0.7 for aCSF, 400 mM NMDA,
400 mM CPP and amphetamine sessions, respectively.
Significant differences in basal efflux were seen when
compared across the four treatment GROUPs (F3, 15 ¼
3.912, P ¼ 0.032). Pair-wise comparisons revealed
that this effect was due solely to differences between
basal levels for 400 mM CPP and amphetamine ses-
sions. However, given the basal levels were stable
across dialysis sessions, and drug treatments were
counterbalanced, it is not likely these differences in
baseline led to such a systematic treatment effect
as described below. Therefore, subsequent analyses
were conducted and reported as percent change from
baseline.
Figure 4 illustrates that the drug treatments led to
differential effects on cortical ACh efflux (GROUP,
F3, 12 ¼ 11.229, P ¼ 0.015). These effects varied
across collection interval (TIME, F8, 32 ¼ 3.894, P ¼
0.003; GROUP  TIME, F24, 96 ¼ 3.204, P < 0.001). A
series of smaller, 2-way ANOVAs were conducted to
look at differences between pairs of treatment groups.
As was the case with the lower concentration of
NMDA (Fig. 2), administration of 400 mM NMDA did
not increase ACh above aCSF vehicle in the PPC
(F1, 4 ¼ 0.084, P ¼ 0.786). As described for the lower
concentration of CPP (Fig. 3), perfusion of 400 mM
Fig. 3. Comparison between ACh efflux measured from the
mPFC and PPC after intra-NAC administration of the NMDA an-
tagonist. Mean (6SEM) ACh efflux in the PPC (n ¼ 6) and mPFC
(n ¼ 9; data collected using identical microdialysis methods and pre-
viously reported in Neigh et al., 2004). In both cases, rats received,
in counterbalanced order, vehicle (aCSF) or CPP alone (200 mM)
into the NAC shell during separate dialysis sessions. Following
baseline collections (Collections 1–4), vehicle or CPP was adminis-
tered for 60 min (Collections 5–8). Upon conclusion of the 60 min
perfusion, aCSF alone was perfused for 30 min until the end of the
dialysis period (Collections 9–11). CPP increased ACh efflux above
vehicle session in the mPFC (Neigh et al., 2004). However, CPP did
not significantly increase ACh above vehicle levels when measured
from the PPC.
Fig. 2. Comparison between ACh efflux measured from the
mPFC and PPC after intra-NAC administration of NMDA. Mean
(6SEM) ACh efflux in the PPC (n ¼ 6) and mPFC (n ¼ 9; data col-
lected using identical microdialysis methods and previously reported
in Zmarowski et al., 2005). In both cases, rats received, in counter-
balanced order, vehicle (aCSF) or NMDA alone (250 mM) into the
NAC shell during separate dialysis sessions. Following baseline col-
lections (Collections 1–4), vehicle or NMDA was administered for
60 min (Collections 5–8). Upon conclusion of the 60 min perfusion,
aCSF alone was perfused for 30 min until the end of the dialysis pe-
riod (Collections 9–11). NMDA increased ACh efflux above vehicle
session in the mPFC (Zmarowski et al., 2005). However, NMDA did
not significantly increase ACh above vehicle levels when measured
from the PPC.
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CPP also failed to increase ACh in the PPC above the
aCSF session (F1, 5 ¼ 0.14, P ¼ 0.91).
Comparable effects of amphetamine in the two
cortical regions
In contrast to the effects of intra-NAC perfusions of
NMDA or CPP, systemic administration of ampheta-
mine (2.0 mg/kg, i.p.) stimulated ACh efflux in both
PFC and PPC (Fig. 5). We have previously reported
that amphetamine stimulates ACh release in PFC
(Nelson et al., 2000) and those data are reproduced in
Figure 5 to highlight the similarity in the drug
response in the two regions of cortex. Amphetamine
markedly stimulated ACh release in PPC relative to
aCSF (GROUP, F1, 5 ¼ 10.195, P ¼ 0.024; TIME,
F10, 50 ¼ 3.862, P ¼ 0.048; GROUP  TIME, F10, 50 ¼
5.188, P ¼ 0.007) in the same animals that were
unaffected by NMDA (Fig. 2) or CPP (Fig. 3). ACh
efflux was significantly higher than aCSF within the
first 15 min following systemic injection (Collection 2
in Fig. 5, t2 ¼ 2.94, P ¼ 0.016). The magnitude of
the stimulated ACh efflux and its duration were com-
parable between the two cortical regions.
The ability of amphetamine to stimulate ACh
release in PPC was also replicated in the group of
animals that received the higher concentrations of
the NMDA ligands (Fig. 4). ACh efflux was higher fol-
lowing amphetamine (2.0 mg/kg, i.p.) than in aCSF
controls (GROUP, F1, 5 ¼ 49.459, P ¼ 0.001; TIME,
F8, 40 ¼ 9.929, P < 0.0001; GROUP  TIME, F8, 40 ¼
11.532, P < 0.0001).
DISCUSSION
The results of these experiments demonstrate that
changes in NMDA receptor activity within the NAC
are not sufficient to stimulate ACh release in PPC.
The inability of intra-NAC perfusions of NMDA or its
antagonist CPP to stimulate ACh release in PPC
stands in contrast with previous reports demonstrat-
ing that these same perfusions markedly increase
ACh release in another cortical region, the PFC
(Neigh-McCandless et al., 2002; Zmarowski et al.,
2005). Furthermore, ACh release in PPC can clearly
be enhanced following a pharmacological treatment
(i.e. amphetamine) that does not necessitate changes
in NAC transmission. The discussion below addresses
several interpretational issues regarding these
results, speculates on the functional implications of
this regional cortical selectivity of NAC modulation,
and presents a hypothesis concerning this regional
difference in the regulation of ACh release.
Intra-NAC perfusions of NMDA or CPP resulted in
a marked stimulation of ACh release in PFC but nei-
ther drug led to significant changes in PPC. This re-
gional selectivity of NAC modulation of cortical ACh
release cannot be attributed to methodological differ-
ences between the current study and our previous
Fig. 5. Mean (6SEM) ACh efflux in the mPFC (n ¼ 8; data
taken from Nelson et al., 2000, using identical microdialysis meth-
ods, for comparison purposes) and PPC (n ¼ 6) of animals receiving
amphetamine (2 mg/kg, i.p). Following 4 h of baseline collection,
amphetamine was systemically administered and collected for eight
subsequent collections. Only the last baseline and first seven collec-
tions are represented for comparison purposes with Nelson et al.,
2000. Administration of amphetamine significantly increased ACh
levels in PPC when compared to vehicle session alone. Moreover,
ACh efflux in PPC following systemic amphetamine is comparable
to levels measured in mPFC.
Fig. 4. Mean (6SEM) ACh efflux in the PPC (n ¼ 6) of animals
receiving, in counterbalanced order, vehicle (aCSF), higher concen-
tration of NMDA (400 mM), or higher concentration of CPP (400 mM)
into the NAC shell during three separate dialysis sessions. Systemic
amphetamine (2 mg/kg, i.p.) was administered as a fourth dialysis
session. Following baseline collections (Collections 1–4), vehicle,
NMDA, or CPP was administered for 60 min (Collections 5–8). Upon
conclusion of the 60 min perfusion, aCSF alone was perfused for
30 min until the end of the dialysis period (Collections 9–11). Amphet-
amine was administered after four baseline collections in a fourth ses-
sion, and ACh was collected for seven subsequent collections (Collec-
tions 5–11). Neither the higher concentration of NMDA or of CPP
increased ACh efflux above vehicle session in the PPC. However, sys-
temic administration significantly increased ACh above baseline.
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reports (Neigh-McCandless et al., 2002; Zmarowski
et al., 2005). The methods and procedures in these
studies were identical, including the coordinates used
for the intra-NAC perfusions. The inability to stimu-
late ACh release in PPC was also not due to a shift in
the dose-response curve for NMDA receptor modula-
tion of the parietal region as doubling the concentra-
tions of either NMDA or CPP was still without effect.
Finally, this regional difference does not reflect a gen-
eral lack of dynamic regulation of ACh release within
PPC. Systemic administration of amphetamine pro-
duced a long-lasting increase in ACh release in PPC
in the same animals in which the lack of effect of
intra-NAC NMDA receptor ligands was documented.
Furthermore, we previously reported stimulation of
ACh release in parietal cortex following several be-
havioral (Himmelheber et al., 1998, 2001; Kozak
et al., 2006) and pharmacological treatments (Fadel
et al., 1999; Moore et al., 1992, 1995). Thus, it would
appear that the observed differences between ACh
release in PFC and PPC were specific to the intra-
NAC perfusion of the NMDA agonist and antagonist.
Recent reports from other laboratories have also
suggested regional differences in the regulation of
cortical ACh release. Regionally specific activation of
ACh release has been demonstrated in visual and
somatosensory following presentation of either visual
or somatosensory cortices stimuli (Fournier et al.,
2004). Visual stimulation was also not associated with
ACh release in prefrontal cortex (Laplante et al.,
2005). Topographical projections from basal forebrain
to sensory cortices may provide an anatomical basis
for such modality-specific activation (Zaborszky, 2002;
Zaborszky et al., 1999, 2005) although regulation of
cortical ACh release by cortico-cortical projections to
the terminal regions may also contribute to regional
differences in ACh release.
Systemic administration of amphetamine differed
from the NMDA ligands in that it was effective in
stimulating ACh release in both PFC and PPC. The
role of the NAC in the mediation of cortical ACh
release following local NMDA or CPP perfusions vs.
systemic amphetamine is different. Previous research
has demonstrated that transmission within the NAC
is not a critical feature of amphetamine-stimulated
ACh release. Direct, intra-NAC perfusions of amphet-
amine were not sufficient to increase cortical ACh
release. Moreover, intra-NAC perfusion of D1- or D2-
like antagonists did not attenuate the ability of sys-
temic amphetamine to stimulate cortical ACh release
(Arnold et al., 2000). The broad, distributed neuronal
system mediating the effects of systemic ampheta-
mine results in the activation of multiple receptor
populations that obviates the regional selectivity of
cortical ACh release (Arnold et al., 2000, 2001).
Before outlining the potential functional implica-
tions of a regional selectivity in the NAC-based modu-
lation of cortical ACh release, the similar effects of
NMDA and its antagonist CPP on PFC ACh warrants
discussion. The fact that both NMDA and CPP
increase ACh release in PFC seems paradoxical, par-
ticularly if one assumes that these drugs are acting
exclusively on the same glutamate receptor popula-
tions in the NAC. While, there is significant overlap
in the distribution of NMDA receptors within the
NAC that are stimulated or blocked by these two
ligands, NMDA and CPP might also influence differ-
ent targets and, hence, projection pathways. The
NMDA receptor is a multimeric complex composed of
an NR1 (NR1a–h) and NR2 (NR2A–D) subunit
(Laube et al., 1997; Wafford et al., 1995). The NR2
subunits impart the distinct pharmacological and
functional properties of the NMDA heterodimer
(Buller et al., 1994). NMDA antagonists such as CPP
demonstrate their highest affinity toward the NR2A
subunit whereas NMDA exhibits its highest affinity
for the NR2B subunit (Feng et al., 2005). To the
extent that these subunits are present to different
degrees on GABAergic interneurons and projection
neurons of the NAC, the two NMDA ligands could
ultimately affect the BFCS in similar fashion but via
different circuits (see Buller et al., 1994; Goebel and
Poosch, 1999; Monaghan and Larsen, 1997). For ex-
ample, by virtue of the distribution of NR2A subunits,
CPP might preferentially block NMDA-mediated ex-
citation of NAC GABAergic projections from shell
to the magnocellular cholinergic neurons of the basal
forebrain. Perfusion of CPP might then render these
cholinergic corticopetal neurons more excitable to
other local inputs. NR2B subunits might be more
heavily distributed on GABAergic interneurons
within NAC or on projections from NAC to VTA.
Thus, direct stimulation of NMDA receptors might
activate a different circuit that still eventuates in the
excitation of the prefrontal cortical cholinergic inputs.
Importantly, in the present context, these specula-
tions do not limit the significance of the central find-
ing of this study. This finding indicates that NAC
manipulations of glutamatergic neurotransmission
influence ACh release in the PFC but not PPC.
Finally, the regional selectivity of the NAC modula-
tion of cortical ACh release might well have been bi-
ased by the manner in which the rats were tested. In
the present experiment and in our previous studies
(Neigh-McCandless et al., 2002; Zmarowski et al.,
2005), rats were tested while awake and freely mov-
ing but, as a result of the extensive habituation to
the testing bowls, the animals remained largely at
rest during the dialysis session. The question remains
whether an NAC-modulated ACh release in PPC
would become evident in animals performing in a be-
havioral task that recruited the BFCS. We have dem-
onstrated that ACh release is increased in both fron-
toparietal (Himmelheber et al., 2001) and posterior
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parietal cortex (Kozak et al., 2006) during perform-
ance of an operant task designed to tax sustained
attention. Such data are not surprising given a num-
ber of studies revealing a role of parietal cortex in
attentional information processing (Broussard et al.
2006; Constantinidis and Steinmetz, 2005; Posner
and Petersen, 1990).
The maintenance or recovery of performance levels
during presentation of a distractor stimulus necessi-
tates top-down controls in attention (Sarter et al.,
2006). We have recently demonstrated that in contrast
to cholinergic transmission in PFC, presentation of a
distractor does not increase ACh release in PPC
beyond those already produced by the onset of the sus-
tained attention task (Kozak et al., 2006). However,
the distractor did produce an additional increase in
ACh release in PPC following selective cholinergic
lesions of the PFC. We interpret this increase in ACh
release as reflecting the neurochemical component of
the increased attentional effort required to maintain
task performance in the absence of PFC-mediated top-
down controls. If cholinergic transmission in PFC is
necessary for optimal top-down control of attention,
and if changes in NMDA receptor activity within NAC
contribute to the activation of these functions of the
PFC, then NAC-modulation of ACh release in PPC
should be evident under conditions that activate such
top-down influences. Ongoing studies will test this hy-
pothesis in task-performing animals under conditions
of intra-NAC perfusion of NMDA ligands with and
without the presentation of visual distractors.
In summary, this experiment demonstrates that
NMDA receptor activity in the NAC can trans-synap-
tically modulate cortical cholinergic transmission.
Under resting conditions, this modulation exhibits a
clear regional difference—affecting ACh release in
PFC but not in PPC. An NAC-based modulation of
prefrontal ACh release may provide the basis for link-
ing motivational factors and attentional processing in
the optimization of goal directed behaviors. Future
studies will determine whether this regional selectiv-
ity of NAC modulation is maintained under conditions
that differentially activate the BFCS.
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